Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies
By Elias Schisgall
Oracle reported a higher profit, buoyed by strong cloud revenue, but logged a decline in software revenue and said the buildout of its artificial-intelligence data-center infrastructure would pressure near-term margins. The stock declined 9.5%, to $182.20, in after-hours trading on Wednesday.
Oxford Industries reported a lower profit, citing the effects of tariff costs and macroeconomic pressures weighing on consumer sentiment. Shares fell 8.7%, to $39.50, after the bell.
Humacyte reported that its bioengineered blood vessel met a primary endpoint in a Phase 3 trial, but announced plans to launch an underwritten public stock offering. The stock was off 12%, to $1.18.
PureCycle Technologies said it would launch a $145 million stock offering and sell $250 million worth of convertible senior notes due 2032. Shares were down 14%, to $8.55.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
June 10, 2026 19:19 ET (23:19 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States